Equities analysts expect OptiNose (NASDAQ:OPTN) to announce ($0.74) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for OptiNose’s earnings. The business is scheduled to announce its next quarterly earnings results on Tuesday, June 12th.

According to Zacks, analysts expect that OptiNose will report full-year earnings of ($3.00) per share for the current financial year, with EPS estimates ranging from ($3.07) to ($2.93). For the next fiscal year, analysts expect that the company will report earnings of ($2.78) per share, with EPS estimates ranging from ($3.00) to ($2.56). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover OptiNose.

How to Become a New Pot Stock Millionaire

OptiNose (NASDAQ:OPTN) last announced its earnings results on Tuesday, March 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.18).

Several equities research analysts recently commented on the company. Zacks Investment Research cut OptiNose from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. Piper Jaffray set a $28.00 price target on OptiNose and gave the company a “buy” rating in a report on Monday, January 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $29.25.

Shares of OptiNose stock traded down $0.26 during mid-day trading on Wednesday, reaching $19.31. 791 shares of the stock traded hands, compared to its average volume of 67,396. OptiNose has a fifty-two week low of $15.01 and a fifty-two week high of $25.24. The company has a debt-to-equity ratio of 0.47, a current ratio of 16.13 and a quick ratio of 15.99.

In related news, CEO Peter K. Miller purchased 5,054 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was purchased at an average price of $18.58 per share, with a total value of $93,903.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new stake in shares of OptiNose in the fourth quarter valued at approximately $162,000. TIAA CREF Investment Management LLC acquired a new stake in OptiNose during the fourth quarter worth $173,000. Teachers Advisors LLC acquired a new stake in OptiNose during the fourth quarter worth $184,000. Millennium Management LLC acquired a new stake in OptiNose during the fourth quarter worth $190,000. Finally, Deutsche Bank AG acquired a new stake in OptiNose during the fourth quarter worth $247,000. 29.49% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/04/16/optinose-optn-expected-to-post-earnings-of-0-74-per-share.html.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.